Bone & Tissue Growth
CJC-1295 & Ipamorelin
GHRH Analogue · Growth Hormone Secretagogue Combination
A synergistic peptide combination that restores youthful growth hormone pulsatility, driving bone density maintenance, collagen production, and cellular regeneration — with significant implications for implant osseointegration and age-related alveolar bone preservation.
What It Is & How It Works
What is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH) that stimulates the pituitary gland to produce and release growth hormone. Unlike direct GH injections, it works through the body's own regulatory feedback system — maintaining natural GH pulsatility rather than overriding it.
What is Ipamorelin?
Ipamorelin is a selective GH secretagogue that mimics ghrelin's GH-releasing action without stimulating cortisol or prolactin. Combined with CJC-1295, it creates a synergistic, physiological pulse of GH that closely mirrors natural youthful release patterns — amplifying the effect of each peptide alone.
Bone & dental application
Optimized GH pulsatility supports osseointegration of dental implants by maintaining osteoblast activity and bone matrix quality. It preserves alveolar bone density in patients experiencing age-related bone loss, accelerates bone graft healing timelines, and promotes systemic collagen turnover that benefits periodontal ligament and TMJ disc integrity.
Key Benefits
- Restores youthful GH pulsatility through the body's own regulatory system — not exogenous hormone replacement
- Supports dental implant osseointegration by maintaining osteoblast activity and bone matrix quality
- Preserves alveolar bone density in patients experiencing age-related bone loss
- Accelerates bone graft healing following ridge augmentation or sinus lift procedures
- Drives IGF-1 production for systemic collagen turnover — benefiting PDL and TMJ disc
- Improves sleep quality and recovery — often a noticed secondary benefit
Key Benefits
Subcutaneous Injection
5 nights per week before sleep — aligns with the body's natural nocturnal GH pulse · full instruction provided
Note: This combination is administered subcutaneously, typically before sleep, to align with the body's natural nocturnal growth hormone pulse. Most protocols run 3–6 months. Your provider will assess bone density markers and treatment response at follow-up appointments.
Possible Side Effects
- Mild water retention in early weeks (resolves)
- Temporary numbness or tingling (carpal tunnel-like, usually transient)
- Vivid dreams (related to improved deep sleep)
- Rare: mild flushing after injection
- Rare: headache
Important Safety Profile
CJC-1295/Ipamorelin works through the body's natural feedback axis and does not suppress endogenous GH production. It carries a meaningfully safer profile than direct GH administration. Patients with active malignancy, diabetic retinopathy, or known pituitary pathology should discuss contraindications with their provider before initiating.
What to Expect
Benefits accrue gradually over 3–6 months. Implant and bone-related benefits are assessed through clinical examination and imaging. Patients commonly notice improvements in sleep quality, recovery, and energy within the first 4–6 weeks. Bone density changes are typically measurable at 3–6 months on DEXA or CBCT imaging.
Regulatory Status
CJC-1295 and Ipamorelin are available as compounded peptides through FDA-regulated compounding pharmacies and prescribed off-label for the indications described above. Your provider will review full regulatory status and provide complete informed consent documentation before treatment begins.